Broker Regulation

Industry observers said that drug companies are likely to continue to oppose the government's efforts to reduce prices.

Plan sponsors must evaluate their current PBM arrangements and decide whether they have a transparent arrangement that they trust or if there is a need to re-evaluate the PBM relationship.

With the price of GLP-1s reaching well over $1000 a month, local officials are warning that rising costs threaten to quickly drain government spending accounts.

Data privacy professionals are keeping an eye on the set of state laws primed to go into effect in 2024.

"I expect that they will be looking for opportunities to apply all of the elements of the guidelines in merger cases -- to some extent, they've already been doing that," said former FTC Chair William Kovacic.

The new year brings a host of new health care industry changes and regulatory compliance issues that will challenge employers--and they'll be looking to their broker partners to help them stay ahead of deadlines and keep abreast of new legislation.

The analysis said the consistently high levels of market concentration can be linked to consolidation of insurers through mergers and acquisition.

The complaint further alleges the defendants knew of the association between GLP-1 receptor agonists and the risk of developing severe gastrointestinal issues but ignored the association and failed to disclose the information they possessed.